INTRODUCTION T
HE HIV INFECTION is an infectious disease characterized by continual decrease of CD4 ϩ lymphocyte cells, invariably causing the death of the host. The amount of CD4 ϩ lymphocyte cells per milliliter and/or the quantity of RNA-HIV-1 copies per milliliter (viral load) are surrogate markers of HIV disease progression. It is known that HIV-positive patients with CD4 ϩ lymphocyte cells counts less than 200 per milliliter are severely immunodepressed, and HIV-positive patients with viral load greater than 10,000 copies per milliliter show an active viremia. 2, 3 In both cases these values are indicators of progression to AIDS.
These markers are also used to indicate success or failure of antiretroviral therapy against HIV. Therefore, they are involved in important clinical decisions. However, for some institutions or populations, for example in developing countries, access to laboratory procedures to determine CD4 ϩ lymphocyte having cell counts and/or viral load, or having the economic resources required to obtain these laboratory data in a routine way, is not possible. On the other hand, it has been reported that lower counts of CD4 lymphocyte cells and higher viral loads are closely related to certain opportunistic infections, including oral lesions related to HIV infection (OL-HIV) specifically oral candidosis (OC) and hairy leukoplakia (HL). [4] [5] [6] [7] Even though the literature concerning the behavior of OL-HIV in patients with HIV/AIDS undergoing highly active antiretroviral therapy (HAART) is scarce, [8] [9] [10] it has been suggested that the presence of OL-HIV could be a clinical indicator of failure of HAART. 11 Therefore, the principal objective of this work is to determine if OL-HIV, specifically OC and HL can be useful clinical indicators of success or failure of HAART.
MATERIALS AND METHODS
Patients with HIV/AIDS from the Internal Medicine Unit of the "Carlos Haya" Hospital, Málaga, Spain, were included in this study. From January 2002 to July 2002 the patients were examined orally. All patients were examined by the same observer, an expert in oral medicine and oral pathology (A.C.S.). The diagnostic criteria used were those proposed by the EC Clearinghouse and the World Health Organization (WHO) for oral disease related to HIV infection. 12 OC diagnosis was based on clinical and symptomatic characteristics and confirmed by positive culture to Candida spp. and morphologic microscopic observation.
All patients included in this study had been receiving HAART (two nucleoside reverse transcriptase inhibitor plus a protease inhibitor of HIV-1, for at least 6 months prior to their oral examination. To be included in the present study the patients with HIV/AIDS should show total compliance to HAART guidelines throughout, confirmed by monthly medical reviews. Clinical history taken at the time of oral examination included the following data: gender, age, route of infection, time of seropositivity, CD4 ϩ lymphocyte cell counts, and viral load. The data were codified in such a way that the biostatistical analysts never knew the demographic, clinical, or paraclinical data. After the data were statistically analyzed and the mathematical model was constructed, the data were decodified.
The experimental design was a transverse model that included the following variables: gender, route of infection and therapy response; dependent independent variables: prevalence of OL-HIV, OC and HL.
All patients were grouped by gender and route of infection: intravenous drug users (IDU), men who have sex with men (MSM), heterosexuals, and hemophiliacs/blood transfusion recipients.
Because the aim of HAART is to decrease to a minimum value the RNA-HIV-1 copies per milliliter the patients were classified as: virologica-responders, patients whose viral load was less than 50 copies per milliliter, and virologic nonresponders, patients whose viral loads were greater than 50 copies per milliliter. On the other hand, because a successful collateral effect of HAART is the increase of CD4 ϩ lymphocyte cell counts, the patients with HIV/AIDS were also classified with respect to their immunologic response capacity as: immunological responders, patients whose CD4 ϩ lymphocyte cell counts were greater than 500 per milliliter; and immunological nonresponders, patients whose CD4 ϩ lymphocyte cell counts were less than 500 per milliliter. As a disconnect, 12 we decided to construct four additional study groups to classify the patients with HIV/AIDS in regard to their virologic and immunologic response in: (1) Total success group when the patients showed a decrease of viral load less than 50 copies per milliliter and also presented a CD4 ϩ lymphocyte cell count greater than 500 per milliliter; (2) viral response group when the viral load diminished but with no increase of CD4 ϩ lymphocytes; (3) paradoxical responders group in patients in whom HAART produced an increase in the amounts of the CD4 ϩ lymphocytes (Ͼ 500 per milliliter) but without a decrease of viral load; and (4) total failure group where no decrease of the viral load nor an increase in the CD4 ϩ lymphocytes were observed.
The prevalence of OL-HIV, OC, and HL by each one of demographic and study groups was also assessed.
All of the variables analyzed were converted into dichotomous variables, with a value ϭ 1 if they are present and the value of 0 if not present. Once the variables were identified an experimental analysis was done using the following procedures: 
RESULTS

Demographic data
One hundred fifty-one patients with HIV/AIDS undergoing HAART were enrolled in the present study. The patients analyzed were grouped as follows: 32 females and 119 males (average age, 37.5 years; range, 19-60 years). In regard to route of infection: 76 were IDUs (11 females, 65 males); 31 were males who have had sex with males (MSM); 37 heterosexuals (19 females and 18 males); 4 hemophiliacs (1 female and 3 males); and 1 patient (a male) in whom the route of infection could not be determined. The hemophiliac patients and the one patient's whose route of infection could not be determined were excluded from statistical analysis. In the total sample of patients with HIV/AIDS examined orally the CD4 ϩ lymphocyte cell average was 381.5 cells (Ϯ255.3), with a range from 5 to 1500 lymphocytes CD4 ϩ per milliliter, and the viral load average was 36,781 copies of RNA-HIV-1 per milliliter (Ϯ118,977.5), with a range from 0 to 750,000 copies of RNA-HIV-1 per milliliter.
In accordance to study groups the patients with HIV/AIDS were classified as follows: 76 patients were classified as virologic nonresponders (18 females and 58 males), and 70 were classified as virologic responders (12 females and 58 males). With respect to immunologic response, there were 40 immunologic responders (4 females, 36 males), while the immunologic nonresponders totalled 106 patients (26 females and 80 males). Also identified were 29 patients with total response; 41 showed viral response; 11 patients had paradoxical response to HAART; and 65 showed total failure to treatment. The patients whose viral loads could not be determined as either CD4 ϩ lymphocyte cells count per milliliter were excluded in the prior classification and were excluded from statistical analysis.
Clinical data
In 69 patients we could observe oral lesions related to HIV infection at a prevalence of 45.6%. Thirty-four of the patients (mean CD4 ϩ lymphocyte cells ϭ 287. 4 Table 1, Table 2, and Table 3 .
Statistical analysis results:
Bivariate analysis. The bivariate analysis showed a difference between OL-HIV prevalence of virological-responders (38.6%) and prevalence of virological nonresponders (55.3%) (p ϭ 0.04). The OL-HIV prevalence of total responders (34.8%) is higher than that of OL-HIV prevalence of the total failure group (58.5%) (p ϭ 0.03) ( Table 1) . With respect to HL there was a significant difference in the prevalence of HL in viral-responders (17.2%) versus the total failure group (36.9%) (p ϭ 0.03) ( Table   2 ). With respect to OC the highest prevalence was found in the immunologic nonresponder group (p ϭ 0.006) and in the total failure group (p ϭ 0.008) ( Table 3) .
Relative risk. The relative risk of OC increases threefold if patients with HIV/AIDS belong to the immunologic nonresponders group: 3.89 95% CI (1.262-12.046) (see Table 2 ).
The total of the bivariate analysis and the relative risk of each group studied for OL-HIV is shown in Table 1 , HL in Table 2 , and OC in Table 3 .
Multiple logistical regression.
No association between OL-HIV and route of infection and viral load was found. Evidence of association between the presence of OC and OL-HIV and immunologic failure was estimated at OR of 9.7 (1.2-78.6).
In the immunologic nonresponder group OR is 5.8 (95% CI 0.7-48.6) if they suffer OC plus Mathematical model. Based on the results of a multiple logistical regression test, a mathematical model was used to assess the probability of patients with HIV/AIDS presenting with immunologic failure if they show oral lesions. The established parameters of the model and the predetermined probabilities for each group was done using the following equation: The probability of patients with HIV/AIDS undergoing HAART presenting with immunologic failure if they have a diagnosis of OC plus OL-HIV plus HL is 85% (95% CI 57%-96%); if they shown OL-HIV plus HL ϭ 5% (95% CI 2%-13%); if they present with OC plus OL-HIV is 91% (95% CI 54%-99%) and if they have a diagnosis of OL-HIV is 66% (95% CI 56%-75%). With regard to route of infection, the probability of patients with HIV/AIDS undergoing HAART presents immune failure if they have a diagnosis of OC is: men who have sex with men is 91%, to heterosexuals, 95.5%, and drug users, 96%.
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DISCUSSION
In the initial era of HIV epidemic, an important diagnostic value was given to two specific opportunistic oral infections: oral candidiasis and hairy leukoplakia. The presence of OC or HL in apparently healthy patients was considered suspicious of HIV infection. 13 Afterwards, it was proposed and accepted that CD4 ϩ lymphocyte cell counts less than 200 per milliliter and RNA copies of HIV-1 greater than 10,000 per milliliter represent advanced stages of HIV infection. Those parameters were established as paraclinical markers of progression of HIV infection. 1 On the other hand a close relation between OC and HL, and severe immunodepression was established. 4, 7 Although data regarding the association of viral load and opportunistic oral infections remains conclusive, a higher prevalence of OC in HIV-positive patients whose viral load were greater than 10,000 copies per milliliter 14, 15 has been reported. For this reason a prognostic value for OC was recognized.
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In the mid 1990s, with the introduction of protease inhibitors of HIV-1 to the antiretroviral therapy HAART was established. HAART produces an important therapeutic effect 16 and dramatic changes in the clinical aspect of HIV infection. So, two periods of the HIV epidemic are recognized: pre-HAART and HAART era. HAART has been directly associated with a decrease in the prevalence of opportunistic infections associated to AIDS, such as Pneumocystis carinii pneumonia, Mycobacterium avium complex infection, cytomegalovirus disease and OCandidiasis. [17] [18] [19] To date, although the data are scarce, it is suggested that OC retains its prognostic value in patients receiving HAART. 20, 21 More recently, it has been suggested that OL-HIV can be used as clinical markers of failure of HAART. 11 Our results show a close relation of OC with immunologic failure in patients with HIV/AIDS undergoing HAART.
HL is another OL-HIV with prognostic value in the pre-HAART era. 7 In the patients with HIV/AIDS undergoing HAART observed in the present study, we cannot establish any relationship between immunologic failure and virologic failure in the presence of HL. Therefore, we suggest that HL did not retain its prognostic value in the HAART era. It has been widely reported that OC is the most prevalent oral opportunistic infections in patients with HIV/AIDS. 13 Nevertheless, in our study, we observed an inversion in prevalence order of opportunistic oral infections. Our results show that most prevalent opportunistic oral infections related to HIV infection is HL. This order of prevalence of HL and OC is present in all demographic groups studied. Recently Tappuni et al. 11 reported the same figure in HIV-positive patients receiving HAART. It could be suggested that the antiretroviral drugs against HIV have no direct action against Epstein-Barr virus and/or that the immunologic reconstitution, interpreted as an increase of CD4 ϩ lymphocyte count, is not associated with a diminishment of HL prevalence.
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The bivariate analysis showed an increase of risk of suffering some type of OL-HIV in the virologic nonresponder group, and furthermore, an increase of OC in the immunologic nonresponders. Nevertheless, the logistical regression model showed evidence of immunologic failure only in those patients with OC and OL-HIV. Patton et al. 19 have emphasized the benefit and necessity to use multivariate statistical analysis.
The use of OC as an auxiliary clinical marker of success or failure of HAART has been suggested. 11 Our results suggested a close association between OC and immunologic failure in patients receiving HAART. Therefore, the presence of this opportunistic mycotic disease of the oral cavity could be indicative of progression of HIV infection and, probably, failure of HAART. The oral lesions associated with HIV infection have advantages as clinical markers: easy access of oral inspection, the diagnostic criteria of oral lesions related to HIV infection are established, 22 ,23 the diagnosis of oral lesions does not require invasive methods, and the low cost involved in the diagnostic procedures. The usefulness of clinical images to monitor patients with HIV/AIDS and the possibility to support therapeutic decisions has been determined. Specifically it has been reported that in areas with limited access to laboratory diagnostic techniques the clinical categories are useful as predictors of survival. 24 Similarly, it has been reported that OC and HL provide important prognostic information and both can be used as a low-cost tool to monitor patients whose financial situation is limited. 25 It is not our intention to negate the importance of the paraclinical markers; however, in situations in which for different reasons the human, technical, or financial resources to obtrain the paraclinical markers are not available, the oral clinical markers of progression of HIV disease can become a useful alternative to support therapeutic decisions.
Our results suggest that OC could be considered as a predictor of immunologic failure in adult patients with HIV/AIDS receiving HAART and also show the possibility of creating a mathematical model for this purpose. We consider that the mathematical model constructed in this work is a useful tool that permits the calculation of the probability of immunologic failure in patients with HIV/AIDS supported by clinical information. Nevertheless, we consider that it is necessary to continue evaluating the relationship between these clinical markers and the failure of anti-HIV treatment. Specifically, it is considered of critical importance to consider the possible influence on the statistical analysis of prior drug resistance against HAART. However, our statistical strategy and the mathematical model constructed in consequence, was a transversal model, and therefore at this time we cannot establish this possible influence. A research protocol designed ex profeso to answer this important query is necessary.
